Total number of patients | 554 |
Median follow-up time | 7.4 Years |
Median age at diagnosis (range) | 57.5 Years (22–85) |
 ≥ 50 years = 402 | |
 < 50 years = 152 | |
Race/ethnicity | White = 500, Black = 29 Hispanic (White or Other) = 14, Asian = 6 Multiracial/Other = 10, Unknown = 8 |
Ki67(%) | Low (≤ 15%) = 104, High (≥ 15%) = 161 |
Tumor stage at Dx | T = 292, T2 = 201, T3 = 41, T4 = 8, Tis = 8 |
Gender | F = 542, M = 12 |
Molecular subtype | TN = 74, ER/PR + ;HER2 +  = 69 ER/PR + ;HER2- = 362, ER/PR-;HER2 +  = 21 ER/PR + , unknown Her2 status = 4 |
Nodal status | N0 = 320, N +  = 230 |
Vital status | Alive = 394, Deceased = 116 Unknown/Lost to follow up = 44 |
Subtype by FISH or IHC | Her2 Type = 12, Luminal = 196 Luminal A = 161, Luminal B = 127 Triple negative = 85 |
Paired samples (Normal) | Yes = 554 |
BRCA1-mutation | Yes = 8, no = 546 |
BRCA2-mutation | Yes = 12, no = 542 |
Tumor histology | Invasive ductal adenocarcinoma = 473 invasive lobular carcinoma = 52 mixed carcinoma = 5, Other = 2 |
Menopausal status | Yes = 244, no = 36 |
Therapy | Any chemotherapy = 390 Neoadjuvant chemotherapy = 75 |
First site of distant metastasis | Visceral = 14, bone = 15, brain/CNS = 2 Skin, other = 5, multiple = 24 |